knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 09:29:56 - browse：7

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

explore

leisure time

WSS

What to watch for from Zogenix and Amicus clinical trials

CDC Director Mandy Cohen on transparency, trust, and health

In his State of the Union, Biden takes clear aim at 'Big Pharma'

RSV shot was 90% effective at preventing hospitalizations in kids

STAT Report: Patient voices and perspectives

How doctors’ personal politics affect patients

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Hepatitis C has a cure — but many Americans still lack access to it

Change Healthcare payments predicted restored March 15

Heart attack and stroke risk calculators need revising

Former reverend arrested for allegedly killing 8

Medical leaders decry Supreme Court decision on affirmative action

Device maker Teleflex to acquire urology company for $600M

As demand for Covid shots wanes, Moderna seeks its next success

Will the FTC rein in IQVIA's health data empire?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The haunting brain science of long Covid

focus

Search called off for baby washed away in Pennsylvania flash flood

RSV shot was 90% effective at preventing hospitalizations in kids

Amylyx ALS drug fails large clinical trial

What to watch for from Zogenix and Amicus clinical trials

How doctors’ personal politics affect patients

The drug industry has found itself all alone in Washington

hotspot

explore

leisure time

entertainment